Program
verducatib
Also written as “BI 1291583”, “Verducatib” and “BI 1291583 mixed with [C-14] BI 1291583”.
In Boehringer Ingelheim’s pipeline, DPP1/CatC inhibitor
. Its studies are mostly in Bronchiectasis · Pulmonary Disease, Chronic Obstructive · Cystic Fibrosis, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 217 open or running | phase 3since Mar 7, 2025 | Jan 22, 2018 | Dec 14, 2026phase 1 · NCT07781631 |
- Named in Boehringer Ingelheim’s own pipeline as
Verducatib (BI 1291583)
, phase 3, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jan 22, 2018.
- Dec 22, 2021Phase 1 study in HealthyNCT05183347 · 36 enrolled · Japan
- Feb 3, 2022Phase 2 study in BronchiectasisNCT05238675 · 322 enrolled · United States, Australia, Belgium and more
- Apr 17, 2023Phase 1 study in HealthyNCT05833035 · 8 enrolled · Netherlands
- Apr 26, 2023Phase 2 study in BronchiectasisNCT05846230 · 268 enrolled · United States, Australia, Belgium and more
- May 10, 2023Phase 2 study in Cystic FibrosisNCT05865886 · 22 enrolled · United States, Belgium, France and more
- Dec 4, 2023Phase 1 study in HealthyNCT06166992 · 14 enrolled · Netherlands
- Oct 7, 2024Phase 1 study in HealthyNCT06631417 · 30 enrolled · Germany
- Jan 20, 2025Phase 1 study in HealthyNCT06791187 · 14 enrolled · Germany
- Feb 13, 2025Named verducatibINNProposed as its International Nonproprietary Name in WHO's List 132 · before, BI 1291583
- Mar 7, 2025Phase 3 study in BronchiectasisNCT06872892 · 1,755 planned · United States, Argentina, Australia and more
- Apr 7, 2025Phase 1 study in HealthyNCT06917872 · 20 enrolled · Germany
- Jun 10, 2025Phase 1 study in HealthyNCT07023354 · 32 planned · United States
- Apr 9, 2026Phase 1 study in HealthyNCT07531628 · 12 enrolled · China
- Aug 7, 20262 phase 1 studies in HealthyNCT07760246, NCT07781631
- Oct 23, 20262 phase 3 studiesNCT07907991, NCT07915219
Ahead
- Dec 14, 2026Primary completion: phase 1 study in HealthyNCT07781631
- Dec 23, 2026Primary completion: phase 1 study in HealthyNCT07023354
- Dec 30, 2026Primary completion: phase 1 study in HealthyNCT07760246
- Mar 31, 2027Primary completion: phase 2 study in BronchiectasisNCT05846230
TargetBeta
“DPP1/CatC inhibitor”the company's pipeline, read by Claude · source
Other programs on CTSC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| brensocatibrule | Insmed | phase 3 | 17 |
| RSS0343 | Jiangsu HengRui Medicine | phase 2 | 5 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07915219Bronchiectasis · United States, Argentina, Austria and more | 3 | Not yet recruiting | Jul 31, 2029 | 1,500 |
| NCT07907991Pulmonary Disease, Chronic Obstructive · United States, Italy, Malaysia | 3 | Not yet recruiting | Nov 12, 2029 | 1,800 |
| NCT07781631Healthy · Germany | 1 | Recruiting | Dec 14, 2026 | 20 |
| NCT07760246Healthy · Germany | 1 | Active, not recruiting | Dec 30, 2026 | 56 |
| NCT07531628Healthy · China | 1 | Completed | Jul 14, 2026 | 12 |
| NCT07023354Healthy · United States | 1 | Recruiting | Dec 23, 2026 | 32 |
| NCT06917872Healthy · Germany | 1 | Completed | Sep 9, 2025 | 20 |
| NCT06872892Bronchiectasis · United States, Argentina, Australia and more | 3 | Recruiting | Jun 15, 2027 | 1,755 |
| NCT06791187Healthy · Germany | 1 | Completed | Feb 21, 2025 | 14 |
| NCT06631417Healthy · Germany | 1 | Completed | Jan 10, 2025 | 30 |
| NCT06166992Healthy · Netherlands | 1 | Completed | Feb 7, 2024 | 14 |
| NCT05865886Cystic Fibrosis · United States, Belgium, France and more | 2 | Completed | Oct 7, 2024 | 22 |
| NCT05846230Bronchiectasis · United States, Australia, Belgium and more | 2 | Active, not recruiting | Mar 31, 2027 | 268 |
| NCT05833035Healthy · Netherlands | 1 | Completed | Jul 5, 2023 | 8 |
| NCT05238675Bronchiectasis · United States, Australia, Belgium and more | 2 | Completed | May 1, 2024 | 322 |
| NCT05183347Healthy · Japan | 1 | Completed | Jul 27, 2022 | 36 |
| NCT04866160Healthy · Germany | 1 | Completed | Nov 30, 2021 | 24 |
| NCT03890887Healthy · Germany | 1 | Completed | Jul 29, 2019 | 14 |
| NCT03868540Healthy · Germany | 1 | Terminated | Nov 25, 2019 | 24 |
| NCT03837964Healthy · Germany | 1 | Completed | Apr 24, 2019 | 12 |
| NCT03414008Healthy · Germany | 1 | Terminated | Nov 18, 2019 | 54 |
How it is read
Names in the registry
- “BI 1291583”, 17 entries
- “Verducatib”, 4 entries
- “verducatib”, 1 entry
- “BI 1291583 mixed with [C-14] BI 1291583”, 1 entry
Conditions, from the studies’ own filings
- Bronchiectasis, 4 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
- Cystic Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.